NeuroCADR: Drug Repurposing to Reveal Novel Anti-Epileptic Drug Candidates Through an Integrated Computational Approach

TL;DR

NeuroCADR is an innovative computational system that integrates multiple machine learning algorithms to identify potential new drug candidates for epilepsy, demonstrating high accuracy and efficiency in drug repurposing.

Contribution

The paper introduces NeuroCADR, a novel multi-algorithm approach for drug repurposing that outperforms existing in silico methods in identifying anti-epileptic drug candidates.

Findings

NeuroCADR achieved high accuracy in drug candidate prediction.

The system identified novel drug candidates for epilepsy.

Potential for personalized drug combination recommendations.

Abstract

Drug repurposing is an emerging approach for drug discovery involving the reassignment of existing drugs for novel purposes. An alternative to the traditional de novo process of drug development, repurposed drugs are faster, cheaper, and less failure prone than drugs developed from traditional methods. Recently, drug repurposing has been performed in silico, in which databases of drugs and chemical information are used to determine interactions between target proteins and drug molecules to identify potential drug candidates. A proposed algorithm is NeuroCADR, a novel system for drug repurposing via a multi-pronged approach consisting of k-nearest neighbor algorithms (KNN), random forest classification, and decision trees. Data was sourced from several databases consisting of interactions between diseases, symptoms, genes, and affiliated drug molecules, which were then compiled into datasets expressed in binary. The proposed method displayed a high level of accuracy, outperforming nearly all in silico approaches. NeuroCADR was performed on epilepsy, a condition characterized by seizures, periods of time with bursts of uncontrolled electrical activity in brain cells. Existing drugs for epilepsy can be ineffective and expensive, revealing a need for new antiepileptic drugs. NeuroCADR identified novel drug candidates for epilepsy that can be further approved through clinical trials. The algorithm has the potential to determine possible drug combinations to prescribe a patient based on a patient's prior medical history. This project examines NeuroCADR, a novel approach to computational drug repurposing capable of revealing potential drug candidates in neurological diseases such as epilepsy.